BACKGROUND: Neurofibromatosis type 2 (NF2) is almost unique among inherited disorders in the frequency of mosaicism in the first affected generation. However, the implications of this on transmission risks have not been fully elucidated. METHODS: The expanded database of 460 families with NF2 and 704 affected individuals was analysed for mosaicism and transmission risks to offspring. RESULTS: 64 mosaic patients, with a projected mosaicism rate of 33% for sporadic classical NF2 with bilateral vestibular schwannoma at presentation and 60% for those presenting unilaterally, were identified. Offspring risks can be radically reduced on the basis of a sensitive mutation analysis of blood DNA including multiple ligation-dependent probe amplification (MLPA, which detects 15% of all mutations), but even MLPA cannot detect high levels of mosaicism. CONCLUSION: The chances of mosaicism in NF2 and the resultant risks of transmission of the mutation to offspring in a number of different clinical situations have been further delineated. The use of MLPA in this large NF2 series is also reported for the first time.
BACKGROUND:Neurofibromatosis type 2 (NF2) is almost unique among inherited disorders in the frequency of mosaicism in the first affected generation. However, the implications of this on transmission risks have not been fully elucidated. METHODS: The expanded database of 460 families with NF2 and 704 affected individuals was analysed for mosaicism and transmission risks to offspring. RESULTS: 64 mosaic patients, with a projected mosaicism rate of 33% for sporadic classical NF2 with bilateral vestibular schwannoma at presentation and 60% for those presenting unilaterally, were identified. Offspring risks can be radically reduced on the basis of a sensitive mutation analysis of blood DNA including multiple ligation-dependent probe amplification (MLPA, which detects 15% of all mutations), but even MLPA cannot detect high levels of mosaicism. CONCLUSION: The chances of mosaicism in NF2 and the resultant risks of transmission of the mutation to offspring in a number of different clinical situations have been further delineated. The use of MLPA in this large NF2 series is also reported for the first time.
Authors: A Moyhuddin; M E Baser; C Watson; S Purcell; R T Ramsden; A Heiberg; A J Wallace; D G R Evans Journal: J Med Genet Date: 2003-06 Impact factor: 6.318
Authors: D G Evans; S M Huson; D Donnai; W Neary; V Blair; D Teare; V Newton; T Strachan; R Ramsden; R Harris Journal: J Med Genet Date: 1992-12 Impact factor: 6.318
Authors: A Mohyuddin; W J Neary; A Wallace; C L Wu; S Purcell; H Reid; R T Ramsden; A Read; G Black; D G R Evans Journal: J Med Genet Date: 2002-05 Impact factor: 6.318
Authors: L M Messiaen; T Callens; G Mortier; D Beysen; I Vandenbroucke; N Van Roy; F Speleman; A D Paepe Journal: Hum Mutat Date: 2000 Impact factor: 4.878
Authors: Michael E Baser; Lisa Kuramoto; Harry Joe; J M Friedman; Andrew J Wallace; James E Gillespie; Richard T Ramsden; D Gareth R Evans Journal: Am J Hum Genet Date: 2004-06-09 Impact factor: 11.025
Authors: Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser Journal: Lancet Date: 2009-05-22 Impact factor: 79.321
Authors: Helen Byers; Yvonne Wallis; Elke M van Veen; Fiona Lalloo; Kim Reay; Philip Smith; Andrew J Wallace; Naomi Bowers; William G Newman; D Gareth Evans Journal: Eur J Hum Genet Date: 2016-06-08 Impact factor: 4.246
Authors: Omar N Pathmanaban; Katherine V Sadler; Ian D Kamaly-Asl; Andrew T King; Scott A Rutherford; Charlotte Hammerbeck-Ward; Martin G McCabe; John-Paul Kilday; Christian Beetz; Nicola K Poplawski; D Gareth Evans; Miriam J Smith Journal: JAMA Neurol Date: 2017-09-01 Impact factor: 18.302
Authors: Miriam J Smith; Andrew J Wallace; Naomi L Bowers; Cecilie F Rustad; C Geoff Woods; Guy D Leschziner; Rosalie E Ferner; D Gareth R Evans Journal: Neurogenetics Date: 2012-03-22 Impact factor: 2.660
Authors: Erin E Salo-Mullen; Jinru Shia; Isaac Brownell; Peter Allen; Monica Girotra; Mark E Robson; Kenneth Offit; Jose G Guillem; Arnold J Markowitz; Zsofia K Stadler Journal: Fam Cancer Date: 2014-09 Impact factor: 2.375